<DOC>
	<DOC>NCT02303171</DOC>
	<brief_summary>Evaluation of shifting to oral vitamin K antagonist after the first trimester instead of using low molecular weight heparin (LMWH) throughout pregnancy in pregnant women with antiphospholipid syndrome (APS)</brief_summary>
	<brief_title>Use of Warfarin After the First Trimester in Pregnant Women With APS</brief_title>
	<detailed_description>Women will be randomly divided into two groups; one will be subjected to anticoagulant therapy by Enoxaparin throughout pregnancy and the other will be subjected to anticoagulant therapy by Enoxaparin in the first trimester then Warfarin after the first trimester until termination of pregnancy.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Abortion, Spontaneous</mesh_term>
	<mesh_term>Antiphospholipid Syndrome</mesh_term>
	<mesh_term>Abortion, Habitual</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Pregnant women with APS diagnosed according to the revised classification criteria for APS in 2006 in Sydney, Australia Early pregnancy body weight is 5090 Kg Women with systemic lupus erythematosus (SLE) Women with active thromboembolic disorders Women with history of previous thromboembolic disorders</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>38 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Antiphospholipid syndrome</keyword>
	<keyword>APS</keyword>
	<keyword>Warfarin</keyword>
</DOC>